New and Updated Results from a Multicenter, Open-Label, Global Phase 3 (P3) Study of Tabelecleucel (Tab-cel) for Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab (R) or Rituximab and Chemotherapy (R+CT) (ALLELE)

Saved in:
Bibliographic Details
Published inTransplantation and cellular therapy Vol. 29; no. 2; pp. S21 - S22
Main Authors Beitinjaneh, Amer, Baiocchi, Robert, Chaganti, Sridhar, Choquet, Sylvain, Dierickx, Daan, Dinavahi, Rajani, Gamelin, Laurence, Ghobadi, Armin, Guzman-Becerra, Norma, Joshi, AJ, Mahadeo, Kris Michael, Mehta, Dr. Aditi, Nikiforow, Sarah, Reshef, Ran, Ye, Wei, Prockop, Susan
Format Journal Article
LanguageEnglish
Published 01.02.2023
Online AccessGet full text

Cover

More Information
ISSN:2666-6367
2666-6367
DOI:10.1016/S2666-6367(23)00094-5